Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 17/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20422674 | 0.78 | MAP4K1 (0.34) | MAP4K1ADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL18237531 | 0.77 | MAP4K1 (0.32) | MAP4K1ADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL23022282 | 0.74 | ADRA2A (0.39) | MAP4K1ADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL29515886 | 0.74 | ADRA2A (0.39) | MAP4K1ADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL21334405 | 0.73 | MAP4K1 (0.46) | MAP4K1 | |
| SCHEMBL16079382 | 0.70 | RET (0.45) | — | |
| SCHEMBL20517531 | 0.70 | MAP4K1 (0.44) | MAP4K1 | |
| SCHEMBL31005741 | 0.70 | MAP4K1 (0.50) | MAP4K1 | |
| SCHEMBL22884682 | 0.70 | MAP4K1 (0.39) | MAP4K1ADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL21334406 | 0.69 | MAP4K1 (0.44) | MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970106-B1 | BORON-CONTAINING DIACYLHYDRAZINES | INTREXON CORP (US) | 2018-05-16 | — | — | EP | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-9512148-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150322092-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION (US) | 2015-11-12 | — | — | US | disclosed |
| US-9127024-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-20140274954-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | MAP4K1 4386/4885ADRA2A 4425/4885ADRA2C 4635/4885 |
| US-20150322092-A1 | Boron-Containing Diacylhydrazines | CD22, BRDT, BCR | MAP4K1 3107/4885ADRA2A 2520/4885ADRA2C 2696/4885 |
| US-20140274954-A1 | Boron-Containing Diacylhydrazines | CD22, BRDT, BCR | MAP4K1 3107/4885ADRA2A 2520/4885ADRA2C 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.